カテゴリ： GlobalData, アメリカ, 企業調査

Karyopharm Therapeutics Inc (KPTI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9864
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：104
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc (KPTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 13
Partnerships 15
Veristat Enters into Agreement with Karyopharm Therapeutics 15
Licensing Agreements 16
Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17
Equity Offering 18
Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18
Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20
Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22
Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23
Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24
Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26
Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28
Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30
Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 32
Debt Offering 34
Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34
Asset Transactions 35
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35
Karyopharm Therapeutics Inc – Key Competitors 36
Karyopharm Therapeutics Inc – Key Employees 37
Karyopharm Therapeutics Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 07, 2018: Karyopharm Reports Second Quarter 2018 Financial Results and Highlights Recent Progress 39
May 10, 2018: Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress 42
Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress 45
Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 48
Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 51
May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 52
Corporate Communications 55
Oct 26, 2018: Karyopharm Therapeutics announces management change 55
Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 56
Apr 03, 2017: Karyopharm Announces Management Change 58
Product News 59
12/10/2017: Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting 59
12/10/2017: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting 61
09/20/2017: Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma 64
06/25/2018: Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 66
06/15/2018: Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting 68
06/01/2018: Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 71
Product Approvals 74
Jul 18, 2018: Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma 74
Apr 10, 2018: Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma 76
Clinical Trials 77
May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 77
May 16, 2018: Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 79
Apr 30, 2018: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma 81
Mar 19, 2018: Karyopharm to Present Preclinical Data On Eltanexor at the American Association for Cancer Research 2018 Annual Meeting 83
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting 84
Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting 85
Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 87
Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 88
Nov 01, 2017: Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting 89
Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 92
Sep 08, 2017: Karyopharm Announces Presentation of Selinexor Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 93
Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 94
Aug 30, 2017: Karyopharm Announces the Presentation of Selinexor Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 95
Aug 08, 2017: Karyopharm Provides Update on Selinexor (KPT-330) 96
Jun 23, 2017: Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting 98
Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma 100
May 18, 2017: Karyopharm’s Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting 101
Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting 102
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104

List of Tables
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 13
Veristat Enters into Agreement with Karyopharm Therapeutics 15
Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 16
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 17
Karyopharm Therapeutics to Raise up to USD75 Million in Public Offering of Shares 18
Karyopharm Therapeutics Raises USD155.2 Million in Public Offering of Shares 20
Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 22
Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 23
Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 24
Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 26
Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 28
Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 30
Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 32
Karyopharm Therapeutics Exercise of Over-Allotment Option of Private Placement of Convertible Senior Notes Due 2025 for USD172.5 Million 34
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 35
Karyopharm Therapeutics Inc, Key Competitors 36
Karyopharm Therapeutics Inc, Key Employees 37
Karyopharm Therapeutics Inc, Subsidiaries 38

List of Figures
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Karyopharm Therapeutics Inc (KPTI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Australian Gas Networks Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Australian Gas Networks Ltd (Australian Gas Networks), formerly Envestra Ltd is an oil and gas company that distributes and transports natural gas. The company's services include managing the haulage of gas through each network, operation and maintenance of gas network, design an constructio …
  • Academic Medical Center-製薬・医療分野：企業M&A・提携分析
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as treatment of patients, medical research and medical education. It provides medical treatments and services for various …
  • Reach PLC：企業の戦略・SWOT・財務分析
    Reach PLC - Strategy, SWOT and Corporate Finance Report Summary Reach PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sulzer Ltd (SUN)：企業の財務・戦略的SWOT分析
    Sulzer Ltd (SUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cap Gemini S.A.：戦略・SWOT・企業財務分析
    Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report Summary Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tokio Marine Asia Pte. Ltd.
    Tokio Marine Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokio Marine Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Virginia Electric and Power Company：企業の発電所・SWOT分析2018
    Virginia Electric and Power Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Bank of Jordan (BOJX)：企業の財務・戦略的SWOT分析
    Summary Bank of Jordan is a banking service provider. The company offers corporate services, leasing services, retail services, SMEs services and securities services. It also provides car loans, mortgage, personal loans and credit cards. Bank of Jordan’s retail services include accounts and deposits …
  • Kobe Steel Ltd：企業のM&A・事業提携・投資動向
    Kobe Steel Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kobe Steel Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Nuvo Pharmaceuticals Inc (NRI)：企業の財務・戦略的SWOT分析
    Summary Nuvo Pharmaceuticals Inc (Nuvo), formerly Nuvo Research Inc, is a healthcare company that offers portfolio of commercial products and pharmaceutical manufacturing capabilities. The company’s product portfolio includes pennsaid, heated lidocaine and tetracaine patches. Its products deliver dr …
  • BCD Travel Services B.V.：戦略・SWOT・企業財務分析
    BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report Summary BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Chevron Nigeria Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Chevron Nigeria Ltd (Chevron Nigeria) a subsidiary of Chevron Corporation is an oil and gas company that offers exploration, production and transportation of crude oil and natural gas. The company distributes products such as additives, jet fuels, base oil, chemical, fuel, lubricant, marine …
  • Vail Resorts Inc：戦略・SWOT・企業財務分析
    Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Vail Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • tella Inc (2191)：製薬・医療：M&Aディール及び事業提携情報
    Summary Tella Inc (Tella) is a drug development company that develops vaccines for cancer treatment. The company offers dendritic cell vaccine therapy which develops dendritic cells to convey the information on cancer markers to lymphocytes and increase the dendritic cell population and strengthen t …
  • Eastman Kodak Company：企業の戦略・SWOT・財務情報
    Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report Summary Eastman Kodak Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PeptiDream Inc (4587)：企業の財務・戦略的SWOT分析
    Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform that helps to produ …
  • TOTAL S.A.：企業の戦略・SWOT・財務情報
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Dyson Group Plc：企業の戦略的SWOT分析
    Dyson Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Commonwealth Scientific and Industrial Research Organisation-製薬・医療分野：企業M&A・提携分析
    Summary Commonwealth Scientific and Industrial Research Organisation (CSIRO) is a national science agency that conducts research in climate adaptation, bio-security, renewable and energy, farming and food production, and information technology, and mining and manufacturing services, and others. The …
  • Agile Therapeutics Inc (AGRX)：企業の財務・戦略的SWOT分析
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆